Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01518725
Other study ID # ED11189
Secondary ID
Status Completed
Phase Phase 4
First received January 18, 2012
Last updated April 27, 2015
Start date January 2012
Est. completion date August 2013

Study information

Verified date April 2015
Source Oklahoma State University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the change in vitamin D status with the change in muscular strength and muscular power in highly trained athletes over a 9-month study period. The investigators hypothesize that the greatest muscular strength and power gains will be demonstrated in the athletes who achieve and maintain a 25(OH)-D > 50 ng/mL (but < 100 ng/mL) over the 6 month study duration.

This hypothesis will be tested by carrying out the following specific aims: Aim 1. to determine the extent to which increasing serum 25(OH)D to > 50 ng/mL is associated with improved muscular power by assessing specific performance measures (e.g. Vertical Jump Test and Wingate test) relative to lean body mass; and Aim 2. to examine the correlation between vitamin D status and muscular power over time.


Description:

Study will be advertised through flyers at the training facilities and by word of mouth. Researchers will schedule meeting with club members at the training facilities. At the meetings, the researchers will give an explanation of the study and address any concerns or questions that they may have. Cyclist will have an opportunity to sign up for participation on a sign-up sheet or e-mail the PI directly to minimize any chance of coercion. Meetings will take place in the training facilities in Tulsa, Oklahoma or the Oklahoma City Metropolitan Area. At this time, subjects will complete an informed consent along with demographic, anthropometric and health history, sunlight exposure, calcium and food frequency questionnaires and PAR Q. All subjects will be asked to fill out the questionnaires in the training facilities at various locations to ensure privacy. After completion of the appropriate questionnaires, cyclist will be have venous blood from the dominant arm (i.e., ~ 5 cc of blood) collected by a licensed medical professional and serum samples stored for future analysis of vitamin D metabolites (i.e., 25-OH-vitamin D and 1,25-OH-vitamin D) and parathyroid hormone (PTH) concentrations. The cyclist's arm will be cleaned with an alcohol swab, the blood will be drawn into a sterile vacutainer using a sterile needle. At the completion of blood collection, the arm will again be cleaned using sterile gauze and covered by a band aid to minimize the risk of infection. Samples will be placed on ice in an ice chest until they are processed in the Nutritional Sciences laboratories at Oklahoma State University. Subjects will then undergo skin tone analyses followed by evaluation of specific performance measures of muscular strength and power. These performance measures include: vertical jump test and a Wingate Power Test. All testing and blood collection will take place at the training facilities.

Within 4 weeks of completing the baseline assessment, the investigators will meet with the cyclist at their training facilities. Participants will be randomly assigned to placebo or the vitamin D supplemented group. The vitamin D supplementation will consist of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. Currently, there is no evidence suggesting that athletes require more vitamin D then the general population for their age. Although we do not anticipate that the dose of vitamin D used in this study, will produce intoxication (150 ng/mL), subjects who exceed 100 ng/ml (i.e., upper end of the normal range) at any time will be asked to discontinue the study. Studies that have demonstrated the benefits of vitamin D supplementation on muscular strength and muscular power have combined vitamin D with calcium. Therefore, all subjects (placebo and vitamin D supplemented group) will be given a commercially available supplement of calcium and instructed to take with breakfast. The calcium supplement is in the form of calcium citrate (500 mg per capsule).


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date August 2013
Est. primary completion date August 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

- Elite Cyclist (level 1,2 or 3)

Exclusion Criteria:

- Currently prescribed vitamin D without physician approval to participate in study

- Participants who respond "yes' to PAR-Q and do not get physician approval to participate in study

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Vitamin D
The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period
Placebo
Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance

Locations

Country Name City State
United States Oklahoma State University Stillwater Oklahoma

Sponsors (2)

Lead Sponsor Collaborator
Oklahoma State University Mid America Athletic Training Association

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Vitamin D status from baseline to 3 months and 6 months Non fasting blood samples will be used for the evaluation of vitamin D metabolites. Venous blood (~5 cc) will be collected from the non-dominant arm by a trained phlebotomist, centrifuged at 2,000 rpm and serum stored at -80° C. Two vitamin D metabolites, 25 (OH) D and 1,25 (OH)2 D and serum PTH will be assessed. Up to 6 months Yes
Primary Change in Power Output from baseline to 3 months and 6 months Power will be assessed using a Vertical Jump Test and a Wingate Power Test. Up to 6 months No
Secondary Sun Exposure Questionnaire Participants will complete a sun exposure questionnaire (SEQ) to estimate vitamin D synthesis. The SEQ is a 2 point questionnaire that assesses exposure in a week's time period. Sun exposure can be calculated by day and by week. This questionnaire is currently in press. Up to 6 months No
Secondary Skin Tone Measurement Skin tone will be assessed using the SmartProbe 400 for skin color measurement (IMS, Inc., Portland, ME). The measurement will be performed on the inner and outer portion of the forearm (dominant arm). Up to 6 months No
Secondary Food Frequency Questionnaire A food frequency questionnaire (FFQ) will estimate dietary vitamin D intake. The FFQ is a 12 point questionnaire that assesses vitamin D supplement usage and the intake of foods that are vitamin D rich. Up to 6 months No
See also
  Status Clinical Trial Phase
Recruiting NCT06061315 - Effect of Collagen Peptides, in Combination With Resistance Training, on Body Composition and Muscle Strength in Untrained Men N/A
Completed NCT01932281 - SierraSil Joint Formula 14 as an Ergogenic Aid to Performance in Athletes N/A
Completed NCT06363669 - Effects of Caffeine-based Supplement on Physical Performance N/A